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Investigations of speciﬁc pathologic mechanisms of a disease
often provide extraordinary opportunities to identify suitable
diagnostic markers and alternative treatment options. We
investigated whether altered protein tyrosine phosphatase (PTP)
activity might be linked to the development of stomach cancer,
which is the most common gastrointestinal malignancy and the
third leading cause of cancer-related death worldwide.1
Perturbations of PTP activity caused by mutations and
manifested as PTP overexpression result in malignant transforma-
tion. Thus, PTPs might serve as alternative diagnostic markers and
anticancer targets. Here, we report an uncommon phosphatase,
PTP non-receptor 21 (PTPN21), which in recent years has been
suspected of playing a pathologic role in gastrointestinal tract
tumorigenesis. A previous mutational analysis of the PTP gene
superfamily identiﬁed PTPN21 as having the highest mutation
frequency in types of colon cancer with microsatellite instability,2
and a later study found that PTPN21 affects mitogenic signaling in
bladder cancer.3 Coincidentally, a systematic expression proﬁling
study of 87 PTPs4 and an independent oligonucleotide microarray
study,5 identiﬁed 22 PTPs (including PTPN21)4 and PTPN21,5
respectively, both studies illustrated distinctly different expression
patterns of PTPN21 in gastric carcinoma and normal gastric tissue.
Our analysis of PTPN21 expression in samples of stomach tissue
obtained from 56 individuals revealed low to medium expression
of PTPN21 in samples of human gastric non-carcinoma
tissue (n= 10; Figure 1a), as well as samples of TNM Classiﬁcation
of Malignant Tumors stage I (n= 4), II (n= 10) and III (n= 23)
human gastric adenocarcinoma tissue. A subgroup analysis of
human stage I gastric carcinoma tissue revealed that PTPN21
expression was signiﬁcantly associated with cytosolic E-cadherin
expression (r= 0.40; P-valueo0.001; Supplementary Figure S1 and
Supplementary Methods and Materials). On a proportional scale,
this suggested an association between PTPN21 and E-cadherin
intensities (r= 0.24; P-valueo0.07). A χ2-test revealed a signiﬁcant
correlation (P-value = 0.01) between PTPN21 levels and the
expression scores for cytosolic E-cadherin, suggesting an inverse
relationship between the expression patterns of membrane
E-cadherin and PTPN21. However, overall PTPN21 is often
expressed at moderate, but largely uniform, levels in virtually all
noncancerous gastric tissues.
Physiologically, PTPN21 directly dephosphorylates ErbB1 and
ErbB4 (members of the receptor tyrosine kinase family),3,6
resulting in upregulation of its downstream signaling. In turn, this
results in the constitutive activation of Src and increases the
activity of ETS domain-containing protein (Elk-1) via regulation of
the MEK-Elk-1 signaling pathway.7 However, not much is known
about PTPN21 and its alternative ErbB4-dependent downstream
targets. Hence, the present study extends our previous work,
which demonstrated that PTPN21 controls the accumulation of
ErbB4 in human embryonic kidney cells and mouse embryonic
cortical neurons.6 In the present study, reciprocal immunopreci-
pitation conﬁrmed that PTPN21 interacts with ErbB4 in SGC 7901
gastric cancer cells (Supplementary Figure S2 and Supplementary
Methods and Materials) in a manner previously described.6
Moreover, ErbB4 is a receptor that is directly upstream of
STAT5,8 and STAT5 activation mediates a wide variety of activities
induced by growth factors, cytokines and interferons. For example,
STAT5 is activated by epidermal growth factor (EGF), which
induces translocation of STAT5 into the nucleus and is highly
expressed in both lymphoma cell lines and clinical samples of
human lymphoma gastrointestinal tissue.9 In addition, STAT5
binds to the gamma-interferon activation motif within the
promoter region of STAT5 target genes to activate transcription
of the pro-survival genes, β-casein and Cyclin D1.10 Such ﬁndings
suggest that PTPN21 expression can induce higher than normal
levels of STAT5 activity in both human B-cell lymphoma and
gastric cells.
To examine the functional consequences of the suggested
association between PTPN21 and STAT5, we analyzed the effect of
PTPN21 on the STAT5 target gene β-casein. PTPN21 promoted
dose-dependent increases (up to 3.1 ± 0.32-fold) in the transcrip-
tion of β-casein, and this induction was further enhanced
5.2 ± 0.43-fold by co-expression of ErbB4 with PTPN21 (Figure 1b
and Supplementary Methods and Materials) in a STAT5A-speciﬁc
manner (Figure 1c). Immunoreactivity assays showed that in SGC
7901 cells, STAT5 levels increased with binding activity in a
PTPN21-dependent manner (Figures 1d and e). The ErbB receptor
antagonist AG1478 blocked all PTPN21-dependent β-casein
transcription, suggesting that the effect of PTPN21 on β-casein is
dependent on the ErbB4 receptor.
Unexpectedly, PTPN21 failed to enhance β-casein translation,
even following EGF stimulation. This discrepancy in translation of
Cyclin D1 and β-casein may be due to differences in the
availability of speciﬁc coactivators required to assemble the
transcriptional coactivator complexes (TCC) for either protein. For
example, it is important to note that STAT5 interacts with Oct1 to
form a TCC needed to promote Cyclin D1 transcription.10 In
addition, STAT5 must also bind to nuclear receptor coactivator 1
(NCOA1) and the glucocorticoid receptor (GR) to form a TCC that
promotes β-Casein transcription.11 This suggests that the β-casein
transcription rates are also dependent on the formation of a
transcription factor complex with NCOA1 and GR; the transcription
reporter assay used in this study accurately reﬂected the
signiﬁcance of PTPN21-dependent STAT5 activation.
Ligand stimulation in HEK 293 cells overexpressing PTPN21
resulted in elevated phosphorylation of STAT5 (Supplementary
Figure S3A; HEK 293), when compared with cells that were either
not treated with an agonist or transfected with the phosphatase-
dead PTPN21 (PD_PTPN21). Expression of Cyclin D1 (another
STAT5 target) was also evaluated, and PTPN21 expression was
positively correlated with Cyclin D1 translation in both HEK 293
and SGC 7901 cells (Supplementary Figure S3B). PTPN21-
dependent STAT5 activity was either absent or only slightly
detectable in non-B-cell lymphoma EL4 cells (Supplementary
Figure S3C). Adding to this complexity, information obtained from
an open-access PrESSTo data set collected by the Fantom
consortium12 described elevated levels of PTPN21 promoter
binding in hematologic cells, but not B cells (Supplementary
Figure S3D). It is important to note that although this study might
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Figure 1. (A) (a–f ) Noncancerous human gastric tissues were stained with anti-PTPN21, and then incubated with Cy3-conjugated secondary
antibody or anti-E-Cadherin antibody. After staining, the samples were incubated with FITC-conjugated secondary antibody to visualize
membrane-localized E-cadherin and total PTPN21 expression. (g–h) Immunohistochemical staining with 3,3′-diaminobenzidine (DAB; brown)
identiﬁed total PTPN21 expression, and hematoxylin (blue) was used as a nuclear counter stain. Scale bar indicates 20 μm. (B) Binding activity
of β-casein promoter-dependent STAT5 obtained from EGF/HB-EGF treated cells was promoted when translating a ﬁreﬂy luciferase (FLuc)
reporter containing PTPN21, but not when translating a control renilla luciferase (RLuc) reporter. The ErbB4 antagonist AG1478 impaired
STAT5 binding activity. The light gray bar indicates cells transfected with empty vector and used as a control. Other bars represent cells
transfected with pcDNA_PTPN21 plasmid in a dose-dependent manner (100–400 ng). Cells were co-transfected with ErbB4 and/or treated
with EGF/HB-EGF (50 ng/ml) or AG1478 (5–10 μM), as indicated. (C) Constitutive STAT5A promoted β-casein promoter-dependent STAT5
binding activity, whereas constitutive STAT5B failed to promote high levels of β-casein promoter-dependent STAT5 binding activity. (D, E) SGC
7901 cells were co-transfected with ErbB4 and PTPN21 or phosphatase-dead mutant PD_PTPN21 for 36–48 h, and then treated with EGF/HB-EGF
(50 ng/ml) for 0, 5 or 30 min as indicated. Immunoblotting analysis revealed enhanced STAT5 activity after transfection with PTPN21, which
manifested as increased phospho (T694)-STAT5 levels. β-Casein expression levels were also analyzed. Total STAT5 protein expression and β-actin
housekeeping protein were used to ensure comparable total protein levels when analyzing different samples. For all tests, a signiﬁcant Po0.05 is
represented with *, a Po0.01 is represented with ** and Po0.001 is represented with ***. Error bars represent the standard deviation.
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have identiﬁed a mechanistic role for PTPN21 in gastric cell lines,
the lymphoma cell line stimulated with EGF showed only a slight
induction of STAT5 activity, suggesting that the erythropoietin
receptor remained the key transmembrane receptor for activation
of STAT5 in the malignant hematopoietic cell line. Taken together,
these data suggest the existence of cross talk between gastric
stroma and adjacent malignant lymphoma cells, triggered by an
extrinsic signaling transduction cross talk mechanism that remains
to be elucidated. As a result, we further investigated the role of
PTPN21 in gastric lymphoma by conducting histopathological
analyses of human gastric B cells obtained from the tissue of
patients with either gastric B-cell Hodgkin’s lymphoma (HL; n = 6)
or non-Hodgkin’s lymphoma (NHL; n = 6).
Gastric B cells from NHL patients contained signiﬁcantly
increased levels of PTPN21; however, when based on intensity
and proportional scales, only moderately increased levels of
PTPN21 were found in B cells from HL patients, and low levels of
PTPN21 in noncancerous tissues (P-valueo0.05; Mann–Whitney U;
Figure 2). Lower expression of membrane E-cadherin was
correlated with a higher expression of PTPN21 in human gastric
B cells obtained from NHL and HL patients. In contrast, expression
of cytosolic E-cadherin was positively correlated with PTPN21
expression in human gastric adenocarcinoma cells. Additional
analyses of the inﬂuence of age and gender were performed using
a ﬁtting linear model and Mann–Whitney U model respectively,
and the results showed no correlation between PTPN21 expres-
sion and age or gender. These results suggest that elevated
PTPN21 expression is both abnormal and involved in the
pathogenesis of gastric B-cell NHL and HL. Overall, based on the
expression proﬁles of PTPN21 in human gastric tissues, it is clear
that PTPN21 plays a less important pathologic role in adenocarci-
noma than in B-cell NHL.
In addition, elevated PTPN21 levels were positively correlated
with cytosolic levels of the carcinoma marker E-cadherin.
Coincidentally, Pez, the Drosophila homolog of PTPN21 that
colocalizes with membrane-bound E-cadherin in basolateral
membranes, is known to be essential for the epithelial-
mesenchymal transition process.13 Overexpression of Pez has
been shown to inhibit cell–cell contact and abolish localization of
E-cadherin to the plasma membrane.13 Such ﬁndings support
those in the present study, which showed that signiﬁcantly
increased PTPN21 expression in malignant human gastric
lymphoma tissue was associated with reduced E-cadherin levels
on the cell membrane (Figure 2).
In summary, PTPN21 was found to be the most mutated PTP in
colorectal tumors with microsatellite instability; however, its role in
human malignancies remains unclear. The data presented in this
report show that PTPN21 is highly expressed in human gastric
Figure 2. (A) PTPN21 is overexpressed in human gastric B-cells non-Hodgkin’s lymphoma tissue. (a–f ) Malignant human gastric B-cells non-
Hodgkin’s lymphoma. (a–d) Fluorescence immunohistochemistry using anti-PTPN21 and Cy3-conjugated secondary antibody or anti-E-
cadherin antibody and FITC-conjugated secondary antibody revealed membrane-localized E-cadherin and total PTPN21 expression. (e–f )
Immunohistochemical staining with 3,3′-diaminobenzidine (DAB; brown) identiﬁed total PTPN21 expression, with hematoxylin (blue) being
used as a nuclear counter stain. (B) Intensity and (C) proportion scores for PTPN21 and E-cadherin expression in noncancerous human gastric
tissues (NC; n = 10), malignant non-Hodgkin’s (NHL; n= 6) and Hodgkin’s lymphoma tissue (HL; n= 6). NHL and HL samples represented by
L. Scale bar indicates 20 μm. For all tests, a signiﬁcant Po0.05 is represented with *, a Po0.01 is represented with ** and Po0.001 is
represented with ***. Error bars represent the standard deviation.
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B-cell NHL tissue, and promotes STAT5 activity. In addition,
moderate levels of PTPN21 expression were identiﬁed in samples
of non-carcinoma gastric tissue. Consequently, our data suggest a
role for PTPN21 in regulating STAT5 activity, and implicate PTPN21
in the tumorigenic process leading to development of
hematologic-related human gastric carcinoma.
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